Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

Código QR

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye

Darrell E White,1 Yang Zhao,2 Abayomi Ogundele,2 Nicole Fulcher,3 Annabel Acs,3 Laura Moore-Schiltz,3 Paul M Karpecki4 1Department of Ophthalmology, SkyVision Centers, Westlake, OH 44145, USA; 2Health Economics and Outcomes Research, Sun Pharmaceutical Industries, Princeton, NJ 08540, USA; 3Outcomes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White DE, Zhao Y, Ogundele A, Fulcher N, Acs A, Moore-Schiltz L, Karpecki PM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	dry eye disease adherence persistence cyclosporine ophthalmic emulsion lifitegrast ophthalmic solution Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0e24e77112774847966722de87e731be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols KK, et al.
Publicado: (2018)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez AL
Publicado: (2018)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
por: Epitropoulos AT, et al.
Publicado: (2020)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Customized anterior segment photoacoustic imaging for ophthalmic burn evaluation in vivo
por: Huangxuan Zhao, et al.
Publicado: (2021)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett IV, et al.
Publicado: (2018)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin D, et al.
Publicado: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography
por: Abdolrahimzadeh B, et al.
Publicado: (2016)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

The Impact of the COVID-19 Pandemic on Ophthalmic Care at an Eye-Specific Emergency Department in an Outbreak Hotspot
por: Moon JY, et al.
Publicado: (2020)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Cyclosporine A micellar delivery system for dry eyes
por: Kang H, et al.
Publicado: (2016)

Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats
por: Dota A, et al.
Publicado: (2020)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian J, et al.
Publicado: (2020)

Changes in Tear Lipid Layer Thickness and Symptoms Following the Use of Artificial Tears with and Without Omega-3 Fatty Acids: ARandomized, Double-Masked, Crossover Study
por: Fogt JS, et al.
Publicado: (2019)

Influence on ocular surface after cataract surgery and effect of topical diquafosol on postoperative dry eye: a multicenter prospective randomized study
por: Miyake K, et al.
Publicado: (2017)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019)

Dermatologists’ Knowledge and Attitudes Toward Dry Eye Disease, Refractive Surgery, and Contact Lenses When Prescribing Isotretinoin in Saudi Arabia
por: Basheikh A, et al.
Publicado: (2020)

Microbial Contamination of Extended Use Ophthalmic Drops in Ophthalmology Clinic
por: Chua SW, et al.
Publicado: (2021)

Addition Of D-Sorbitol Improves The Usability Of Ophthalmic Viscosurgical Devices
por: Watanabe I, et al.
Publicado: (2019)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah RT, et al.
Publicado: (2019)

Reduction in Ophthalmic Presentations to Australian Emergency Departments During the COVID-19 Period: Are We Seeing the Full Picture?
por: Kam AW, et al.
Publicado: (2021)

A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide) nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole
por: Ahmed TA, et al.
Publicado: (2017)

Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles
por: Nagai N, et al.
Publicado: (2019)

Predictors of Poor Plasma Glucose Maintenance in Type II Diabetic People with Ophthalmic Complication: The Case of Dessie Hospitals in Ethiopia
por: Abdu Seid M, et al.
Publicado: (2021)

Clinical utility of antimicrobial susceptibility measurement plate covering formulated concentrations of various ophthalmic antimicrobial drugs
por: Tou N, et al.
Publicado: (2016)

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
por: Brooks CC, et al.
Publicado: (2020)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

Interactive navigation-guided ophthalmic plastic surgery: assessment of optical versus electromagnetic modes and role of dynamic reference frame location using navigation-enabled human skulls
por: Ali MJ, et al.
Publicado: (2016)

Oxidative stress and its downstream signaling in aging eyes
por: Pinazo-Durán MD, et al.
Publicado: (2014)